Opinion|Videos|April 7, 2025
The Future of DLBCL: Innovations in Therapy and Patient Care
Panelists discuss how the treatment landscape for diffuse large B-cell lymphoma (DLBCL) is poised for transformation as novel chimeric antigen receptor T-cell approaches integrate with existing therapies, enhancing efficacy and durability. Insights from Tandem 2025 highlight advancements in cellular therapy, including combinatorial strategies and next-generation chimeric antigen receptor T-cell designs, driving optimism for improved patient outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you envision the treatment landscape evolving over the next few years as we integrate novel chimeric antigen receptor T-cell approaches with other available therapies?
- What excites you most about the future of cellular therapy in diffuse large B-cell lymphoma based on the research and clinical advances discussed at Tandem 2025?
Advertisement
Related to this article
Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
In the phase 2 DALY 2-EU trial, zamto-cel prolonged median event-free survival vs R-GemOx in transplant-ineligible relapsed/refractory large B-cell lymphoma.
Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
Grade 3/4 neurotoxicity in patients prompted a partial clinical hold on the PALISADES-1 and PALISADES-2 trials of KITE-753 in large B-cell lymphoma.
In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
2
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
3
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
4
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
5